Published in Biol Blood Marrow Transplant on September 12, 2016
Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care. Biol Blood Marrow Transplant (2016) 0.75
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes. Biol Blood Marrow Transplant (2016) 0.75
Signatures of mutational processes in human cancer. Nature (2013) 21.63
A review of human carcinogens--Part B: biological agents. Lancet Oncol (2009) 13.85
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet (2007) 11.06
Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol (2005) 7.57
Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med (2010) 7.20
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 5.80
A review of human carcinogens--Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol (2009) 5.15
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Telomeres and aging. Physiol Rev (2008) 4.79
Solid cancers after bone marrow transplantation. N Engl J Med (1997) 4.62
A review of human carcinogens--part D: radiation. Lancet Oncol (2009) 4.22
Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood (2008) 3.85
Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. Cell Host Microbe (2010) 3.78
Telomere length and risk of incident cancer and cancer mortality. JAMA (2010) 3.55
The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2011) 3.29
Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res (1998) 2.93
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood (2009) 2.73
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med (1993) 2.52
XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis (2001) 2.35
Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med (2014) 2.33
Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol (2011) 2.31
Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol (2010) 2.25
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol (2014) 2.24
New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol (2003) 2.19
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood (2005) 2.04
Solid cancers after bone marrow transplantation. J Clin Oncol (2001) 1.99
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood (2008) 1.98
Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood (2004) 1.97
Genome-wide association study of glioma and meta-analysis. Hum Genet (2012) 1.96
Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica (2007) 1.95
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood (2012) 1.93
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2006) 1.87
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol (2010) 1.84
Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood (1996) 1.77
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood (2000) 1.74
Variation at the TERT locus and predisposition for cancer. Expert Rev Mol Med (2010) 1.74
Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood (2005) 1.73
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol (2015) 1.70
Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood (2003) 1.59
Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med (1999) 1.59
In vivo telomere dynamics of human hematopoietic stem cells. Proc Natl Acad Sci U S A (1997) 1.58
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood (2002) 1.57
Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect (2003) 1.55
Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica (2005) 1.45
Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol (1999) 1.45
Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group. J Clin Oncol (2001) 1.43
Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol (2006) 1.42
Provider counseling about health behaviors among cancer survivors in the United States. J Clin Oncol (2007) 1.42
The origin of epithelial neoplasms after allogeneic stem cell transplantation. Haematologica (2006) 1.39
Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci U S A (2001) 1.39
A review of human carcinogens--Part A: pharmaceuticals. Lancet Oncol (2009) 1.39
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood (2010) 1.38
T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol (2012) 1.36
Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant (2013) 1.30
Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr (2014) 1.30
Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol (2009) 1.29
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant (2012) 1.28
Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood (2013) 1.21
Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res (2004) 1.20
Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol (2013) 1.20
The preventive health behaviors of long-term survivors of cancer and hematopoietic stem cell transplantation compared with matched controls. Biol Blood Marrow Transplant (2009) 1.18
Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood (1999) 1.18
Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transplant (2014) 1.15
Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol (1999) 1.13
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood (2004) 1.09
Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. Eur J Clin Invest (2008) 1.08
Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol (2007) 1.07
Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood (2009) 1.06
Telomere biology in hematopoiesis and stem cell transplantation. Blood Rev (2011) 1.05
First report of donor cell-derived acute leukemia as a complication of umbilical cord blood transplantation. Blood (2005) 1.04
Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia (2005) 1.04
Cutaneous squamous cell carcinoma and human papillomavirus: is there an association? Dermatol Surg (2012) 1.03
Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation. Stem Cells (2007) 1.03
Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors. Bone Marrow Transplant (2006) 1.01
National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines. Biol Blood Marrow Transplant (2012) 1.01
Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation. Blood (2012) 1.01
Telomere length changes in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant (1999) 1.00
Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant (2010) 0.98
Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation. Blood (2008) 0.98
Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source. Bone Marrow Transplant (2013) 0.98
Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation survivor study. Biol Blood Marrow Transplant (2013) 0.97
Donor cell derived acute myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T-cell lymphoma. Am J Hematol (2005) 0.97
Secondary solid tumors after allogeneic hematopoietic SCT in Japan. Bone Marrow Transplant (2011) 0.96
Can routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation? Clin Cancer Res (2009) 0.96
Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Marrow Transplant (2005) 0.96
Oral malignancies following HSCT: graft versus host disease and other risk factors. Oral Oncol (2005) 0.96
Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning. Haematologica (2011) 0.95
Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant (2009) 0.95
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant (2012) 0.95
Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol (1994) 0.95
Late toxicity in children undergoing hematopoietic stem cell transplantation with TBI-containing conditioning regimens for hematological malignancies. Strahlenther Onkol (2009) 0.95
Health behaviors and cancer screening practices in long-term survivors of hematopoietic cell transplantation (HCT): a report from the BMT Survivor Study. Bone Marrow Transplant (2011) 0.94
Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant (2003) 0.93
Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. Radiat Res (2009) 0.92
Bone mineral density in children with fanconi anemia after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2015) 0.81
Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biol Blood Marrow Transplant (2016) 0.78
The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biol Blood Marrow Transplant (2016) 0.77
Cardiovascular Function in Long-Term Hematopoietic Cell Transplantation Survivors. Biol Blood Marrow Transplant (2017) 0.75
Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation (HCT) for Inherited Bone Marrow Failure Syndromes (IBMFS): Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant (2017) 0.75
Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents. Biol Blood Marrow Transplant (2014) 0.75
Endocrinopathies, Bone Health, and Insulin Resistance in Patients with Fanconi Anemia after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant (2016) 0.75
Recommendations for Screening and Management of Late Effects in SCID Patients after Allogenic Hematopoietic Cell Transplantation (HCT): A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant (2017) 0.75
Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Inherited Bone Marrow Failure Syndromes (IBMFS): Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant (2017) 0.75
Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less Than Three Years of Age. Biol Blood Marrow Transplant (2017) 0.75
Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant (2017) 0.75
Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Children with Sickle Cell Disease and Thalassemia: a Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant (2017) 0.75
PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer (2017) 0.75